Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15016646 | 1.00 | SLC6A1 (0.55) | SLC6A1TSHRSMN1; SMN2SLC6A11LMNA | |
| SCHEMBL16036865 | 0.91 | CHRNB2 (0.56) | SLC6A1TSHRSMN1; SMN2SLC6A11LMNA | |
| SCHEMBL12696525 | 0.91 | CHRNB2 (0.56) | SLC6A1TSHRSMN1; SMN2SLC6A11LMNA | |
| Hydrochloric Acid SCHEMBL2146404 | 0.89 | CHRNB2 (0.54) | SLC6A1TSHRSMN1; SMN2SLC6A11LMNA | |
| Hydrochloric Acid SCHEMBL2146410 | 0.89 | CHRNB2 (0.54) | SLC6A1TSHRSMN1; SMN2SLC6A11LMNA | |
| SCHEMBL29542788 | 0.86 | SLC6A1 (0.49) | SLC6A1TSHRSMN1; SMN2SLC6A11LMNA | |
| SCHEMBL29541720 | 0.85 | SLC6A1 (0.47) | SLC6A1TSHRSMN1; SMN2SLC6A11LMNA | |
| SCHEMBL29542334 | 0.85 | SMN1; SMN2 (0.47) | SLC6A1TSHRSMN1; SMN2SLC6A11LMNA | |
| SCHEMBL25773264 | 0.83 | SLC6A1 (0.49) | SLC6A1TSHRSMN1; SMN2SLC6A11LMNA | |
| SCHEMBL19531885 | 0.82 | CHRNB2 (0.69) | TSHRSMN1; SMN2CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688890-B1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2017-08-30 | — | — | EP | claimed |
| US-9115133-B2 | Substituted fused tricyclic compounds, compositions and medicinal applications thereof | ADVINUS THERAPEUTICS LIMITED (US) | 2015-08-25 | — | — | US | claimed |
| US-20140023614-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD. | 2014-01-23 | — | — | US | claimed |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
| CN-108349969-B | Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors | 阵列生物制药公司 | 2022-05-10 | — | — | CN | disclosed |
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | IDORSIA PHARMACEUTICALS LTD. (CH) | 2022-04-19 | — | — | US | disclosed |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
| WO-2021076617-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20200216423-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-07-09 | — | — | US | disclosed |
| WO-2020025517-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-02-06 | — | — | WO | disclosed |
| EP-2688890-B1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2017-08-30 | — | — | EP | disclosed |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| WO-2012127506-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-09-27 | — | — | WO | disclosed |
| US-20110245272-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2011-10-06 | — | — | US | disclosed |
| US-20110245272-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2011-10-06 | — | — | US | disclosed |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100152163-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2010-06-17 | — | — | US | disclosed |
| US-20100022580-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. | 2010-01-28 | — | — | US | disclosed |
| US-20100022580-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. | 2010-01-28 | — | — | US | disclosed |
| WO-2009094668-A1 | NEW 2,3,4,5-TERAHYDRO-1H-PYRIDO[ 4,3-B] INDOLE COMPOUNDS AND METHODS OF USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245272-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | SLC6A1 284/4885TSHR 839/4885SMN1; SMN2 2610/4885 |
| US-20140023614-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | MALT1, JAK1, ICOS | SLC6A1 2525/4885TSHR 122/4885SMN1; SMN2 1512/4885 |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | SLC6A1 277/4885TSHR 847/4885SMN1; SMN2 2604/4885 |
| US-20100022580-A1 | NEW 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLE COMPOUNDS AND METHODS OF USE THEREOF | HTR2C, HTR3B, HTR4 | SLC6A1 256/4885TSHR 819/4885SMN1; SMN2 2787/4885 |
| US-11306078-B2 | Piperidine CXCR7 receptor modulators | CXCR1, CXCR5, ACKR3 | SLC6A1 2342/4885TSHR 246/4885SMN1; SMN2 4303/4885 |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | SLC6A1 319/4885TSHR 1922/4885SMN1; SMN2 945/4885 |
| US-20200216423-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | SLC6A1 2395/4885TSHR 2126/4885SMN1; SMN2 4740/4885 |
| US-20100152163-A1 | AZEPINO[4,5-B]INDOLES AND METHODS OF USE | HTR2C, HTR5A, HTR4 | SLC6A1 405/4885TSHR 480/4885SMN1; SMN2 4536/4885 |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | SLC6A1 4553/4885TSHR 705/4885SMN1; SMN2 2516/4885 |
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | YTHDF1, YTHDF3, YTHDF2 | SLC6A1 4766/4885TSHR 2302/4885SMN1; SMN2 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.